Trebananib (AMG 386)

AMG 386 is a peptibody that binds to and inhibits angiopoietin 1 and 2. It is being investigated as a cancer treatment. AMG 386 has a new mechanism of action different from other anti-angiogenesis drugs: it inhibits angiogenesis by preventing interaction between angiopoietins and Tie2 receptor tyrosine kinases. AMG 386 is being tested in combinations with many other drugs including sorafenib and sunitinib in Phase II trials.

Manufacturer: AMGEN, home page: http://www.amgen.com/

Definintion from NCI Drug Dictionary:  An angiopoietin (Ang) 1 and 2 neutralizing peptibody, with potential antiangiogenic activity. Trebananib targets and binds to Ang1 and Ang2, thereby preventing the interaction of the angiopoietins with their target tie2 receptors. This may inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.

Click here to download results of a completed Phase I trial.

Link here to a current Phase II trial for which GIST patients may be eligible.

The following free-access paper describes involvement of angiopoietin and tie targets in GISTs:
Expression of angiopoietin-1, 2 and 4 and Tie-1 and 2 in gastrointestinal stromal tumor, leiomyoma and schwannoma.
Nakayama T, Inaba M, Naito S, Mihara Y, Miura S, Taba M, Yoshizaki A, Wen CY, Sekine I.
World J Gastroenterol. 2007 Sep 7;13(33):4473-9.